[go: up one dir, main page]

BR9910095A - Compostos inibidores de spla2 para tratamento de doença - Google Patents

Compostos inibidores de spla2 para tratamento de doença

Info

Publication number
BR9910095A
BR9910095A BR9910095-9A BR9910095A BR9910095A BR 9910095 A BR9910095 A BR 9910095A BR 9910095 A BR9910095 A BR 9910095A BR 9910095 A BR9910095 A BR 9910095A
Authority
BR
Brazil
Prior art keywords
disease treatment
inhibitor compounds
spla2 inhibitor
spla
inhibitor
Prior art date
Application number
BR9910095-9A
Other languages
English (en)
Inventor
William Louis Macias
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9910095A publication Critical patent/BR9910095A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS INIBIDORES DE sPLA~ 2~ PARA TRATAMENTO DE DOENçA''<D>. é revelado um processo para tratamento de doença inflamatória do intestino, por administração a um ser humano que necessite, de uma quantidade terapeuticamente eficaz de um inibidor de sPLA~ 2~,tal como, inibidor de sPLA~ 2~ de 1H-indol-3-glioxilamida.
BR9910095-9A 1998-05-01 1999-04-20 Compostos inibidores de spla2 para tratamento de doença BR9910095A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8387498P 1998-05-01 1998-05-01
PCT/US1999/008654 WO1999057100A1 (en) 1998-05-01 1999-04-20 Spla2 inhibitor compounds for treatment of disease

Publications (1)

Publication Number Publication Date
BR9910095A true BR9910095A (pt) 2000-12-26

Family

ID=22181224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910095-9A BR9910095A (pt) 1998-05-01 1999-04-20 Compostos inibidores de spla2 para tratamento de doença

Country Status (20)

Country Link
US (1) US6340699B1 (pt)
EP (1) EP1084108A4 (pt)
JP (1) JP2002513783A (pt)
KR (1) KR20010043190A (pt)
CN (1) CN1299348A (pt)
AU (1) AU3656299A (pt)
BR (1) BR9910095A (pt)
CA (1) CA2330856A1 (pt)
CZ (1) CZ20004052A3 (pt)
EA (1) EA200001140A1 (pt)
HR (1) HRP20000739A2 (pt)
HU (1) HUP0102243A2 (pt)
ID (1) ID27153A (pt)
IL (1) IL139019A0 (pt)
NO (1) NO20005479L (pt)
PL (1) PL343708A1 (pt)
SK (1) SK16342000A3 (pt)
TR (1) TR200003194T2 (pt)
WO (1) WO1999057100A1 (pt)
ZA (1) ZA200005563B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
US7026318B2 (en) 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect
JP2004504446A (ja) * 2000-07-24 2004-02-12 ダウ　グローバル　テクノロジーズ　インコーポレイティド 熱可塑性超吸収性ポリマーブレンド組成物および該組成物の調製
AU2006311766A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having C4-acidic substituents and use thereof as phospholipase-A2 inhibitors
US20110009379A1 (en) * 2008-04-01 2011-01-13 Astellas Pharma Inc. Indolinone compound
US20120093922A1 (en) 2009-04-29 2012-04-19 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US9290752B2 (en) 2013-03-13 2016-03-22 Sunny Delight Beverages Co. Process for enhancing the amylase inhibitory efficacy from phaseolus vulgaris extracts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356919A (en) 1991-05-30 1994-10-18 G. D. Searle & Co. Leukotriene B4 synthesis inhibitors
DE4218096A1 (de) 1992-06-02 1993-12-09 Boehringer Mannheim Gmbh Spiro-oxetane, Verfahren zu ihrer Herstellung und Arzneimittel
DE4323409A1 (de) 1993-07-13 1995-01-19 Boehringer Mannheim Gmbh Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel
AU688458B2 (en) 1994-04-01 1998-03-12 Eli Lilly And Company 1H-indole-3-glyoxylamide sPLA2 inhibitors
WO1995033462A1 (en) * 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds
NZ298145A (en) * 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
BR9713261A (pt) 1996-10-30 2000-03-28 Lilly Co Eli Tricìclicos substituìdos
CN1310706A (zh) * 1998-02-25 2001-08-29 遗传研究所有限公司 磷脂酶抑制剂

Also Published As

Publication number Publication date
CA2330856A1 (en) 1999-11-11
SK16342000A3 (sk) 2002-04-04
CZ20004052A3 (cs) 2002-05-15
US6340699B1 (en) 2002-01-22
ID27153A (id) 2001-03-08
JP2002513783A (ja) 2002-05-14
NO20005479D0 (no) 2000-10-31
HRP20000739A2 (en) 2001-10-31
CN1299348A (zh) 2001-06-13
NO20005479L (no) 2000-12-20
AU3656299A (en) 1999-11-23
EP1084108A1 (en) 2001-03-21
EP1084108A4 (en) 2005-01-12
WO1999057100A1 (en) 1999-11-11
PL343708A1 (en) 2001-08-27
KR20010043190A (ko) 2001-05-25
EA200001140A1 (ru) 2001-04-23
HUP0102243A2 (hu) 2001-10-28
ZA200005563B (en) 2002-01-10
IL139019A0 (en) 2001-11-25
TR200003194T2 (tr) 2001-03-21

Similar Documents

Publication Publication Date Title
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson&#39;s disease
ES2191069T3 (es) Diaril-2-(5h)-furanonas como inhibidores de cox-2.
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
PT1309589E (pt) Compostos de ureia e metodos de utilizacao
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
ATE189218T1 (de) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
SI1456380T1 (sl) Smad inhibitorji za zdravljenje cns bolezni
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
ATE357453T1 (de) Comt-inhibitoren
CO5180578A1 (es) Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
YU75803A (sh) Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
BR9910095A (pt) Compostos inibidores de spla2 para tratamento de doença
BR0314081A (pt) Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase
PT1206444E (pt) Compostos que inibem a actividade da triptase
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
HRP20041150A2 (en) Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]